BioXcel Therapeutics Inc Market Cap ($1.60 Million)
Market Cap & Net Worth: BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc market cap. BioXcel Therapeutics Inc (NASDAQ:BTAI) has a market capitalization of $1.60 Million ($1.60 Million) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30275 globally and #6176 in its home market, demonstrating a -52.34% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioXcel Therapeutics Inc's stock price $0.05 by its total outstanding shares 31305499 (31.31 Million). Also see BTAI cash flow conversion for how efficiently the company converts equity into cash flow.
BioXcel Therapeutics Inc Market Cap History (2018–2026)
BioXcel Therapeutics Inc market cap history from 2018 to 2026. Data shows change from $120.84 Million to $1.60 Million (-46.81% CAGR). Check BioXcel Therapeutics Inc share price for real-time trading data and today's change.
Index Memberships
BioXcel Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #882 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2808 of 3165 |
Weight: BioXcel Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioXcel Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioXcel Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of BioXcel Therapeutics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
78.02x
BioXcel Therapeutics Inc's market cap is 78.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.45 Billion | $24.30 | -$82.01 Million | 59519096.86x | N/A |
| 2022 | $672.44 Million | $375.00K | -$165.76 Million | 1793.18x | N/A |
| 2023 | $92.35 Million | $1.38 Million | -$179.05 Million | 66.92x | N/A |
| 2024 | $11.71 Million | $2.27 Million | -$59.60 Million | 5.17x | N/A |
| 2025 | $50.09 Million | $642.00K | -$69.90 Million | 78.02x | N/A |
Competitor Companies of BTAI by Market Capitalization
Companies near BioXcel Therapeutics Inc in the global market cap rankings as of November 3, 2026. Also see how large is BioXcel Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to BioXcel Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of BioXcel Therapeutics Inc (2018–2026)
Market capitalization of BioXcel Therapeutics Inc from 2018 to today. Between 2018 and today, BioXcel Therapeutics Inc's market cap moved from $120.84 Million to $ 1.60 Million, with a yearly change of -46.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.60 Million | -96.81% |
| 2025 | $50.09 Million | +327.92% |
| 2024 | $11.71 Million | -87.33% |
| 2023 | $92.35 Million | -86.27% |
| 2022 | $672.44 Million | +5.66% |
| 2021 | $636.44 Million | -56.00% |
| 2020 | $1.45 Billion | +216.22% |
| 2019 | $457.37 Million | +278.50% |
| 2018 | $120.84 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of BioXcel Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.60 Million USD |
| MoneyControl | $1.60 Million USD |
| MarketWatch | $1.60 Million USD |
| marketcap.company | $1.60 Million USD |
| Reuters | $1.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. I… Read more